Key result
Bioinformatics analysis identifies up-regulated MMP9 in both atherosclerosis and nonalcoholic fatty liver disease.
Why the study?
Atherosclerosis is closely related to nonalcoholic fatty liver disease, which promotes and exacerbates atherosclerosis development, but the precise underlying mechanism remains uncertain.
MMP9 is identified as a co-expressed, up-regulated gene in both atherosclerosis and NAFLD, suggesting a shared immune and inflammatory mechanism and highlighting it as a potential therapeutic target.
Hypothesis-generating for MMP9 as shared biomarker in atherosclerosis and NAFLD; prospective validation required before clinical consideration.
Atherosclerosis (AS) is closely related to nonalcoholic fatty liver disease (NAFLD), which promotes and exacerbates the development of AS. However, it is uncertain how the precise underlying mechanism occurs. Here, we attempted to further explore the association underlying atherosclerosis and nonalcoholic fatty liver disease through integrated bioinformatics analysis. Microarray data for atherosclerosis and nonalcoholic fatty liver disease were retrieved from the Gene Expression Omnibus (GEO) database. Weighted gene co-expression network analysis (WGCNA) was used to identify the genes related to atherosclerosis and nonalcoholic fatty liver disease showing co-expression. Additionally, the common gene targets associated with atherosclerosis and nonalcoholic fatty liver disease were also analyzed and screened using data from 3 public databases [comparative toxicogenomics database (CTD), DISEASES, and GeneCards]. The Gene Ontology (GO) enrichment analysis and the Kyoto encyclopedia of genes and genomes (KEGG) enrichment analysis were performed using Metascape R, respectively. The protein-protein interaction networks (PPI) network was constructed using Cytoscape. According to the results of an analysis of common genes, matrix metalloproteinase 9 (MMP9) is co-expressed up-regulated in AS and NAFLD and is enriched in inflammatory and immune-related collaterals. Consequently, MMP9 may work together through immunity and inflammation to treat AS and NAFLD and may be a potential therapeutic target in the future. The findings of this study provide new insights into the shared association between AS and NAFLD. MMP9 is co-expressed up-regulated in AS and NAFLD, which be able to reveal the presence of co-expressed genes in atherosclerosis and NAFLD.
No takes yet. Share an insight, caveat, or question.
Lv et al. (2024) studied Atherosclerosis and nonalcoholic fatty liver disease. Atherosclerosis and nonalcoholic fatty liver disease was evaluated on Identification of co-expressed genes. Integrated bioinformatics analysis revealed that matrix metalloproteinase 9 (MMP9) is co-expressed and up-regulated in both atherosclerosis and nonalcoholic fatty liver disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: